MIG
ACHN

Mariner Investment Group’s Achillion Pharmaceuticals ACHN Stock Holding History

Mariner Investment Group’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-124,200
Closed -$1.34M – 229
2015
Q4 		$1.34M Sell
124,200
-60,800
-33% -$553K 0.3% 102
2015
Q3 		$1.28M Hold
185,000
– – 0.26% 103
2015
Q2 		$1.64M Buy
+185,000
New +$1.75M 0.42% 85

Other funds holding ACHN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Mariner Investment Group's ACHN Position: Q1 2016 in Review

Mariner Investment Group sold out of Achillion Pharmaceuticals (ACHN) in Q1 2016, closing a stake of 124,200 shares — an estimated $1.34M sold.

Mariner Investment Group first reported a position in ACHN in Q2 2015 and held it in 3 quarters. The position peaked at $1.64M in Q2 2015. 153 funds tracked by Wall St. Rank hold ACHN as of Q1 2016.

  • Mariner Investment Group reported no remaining Achillion Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Mariner Investment Group sold 124,200 Achillion Pharmaceuticals shares in Q1 2016, an estimated $1.34M.
  • Mariner Investment Group first reported a position in Achillion Pharmaceuticals in Q2 2015 and held it in 3 quarters.
  • Mariner Investment Group's Achillion Pharmaceuticals position peaked at $1.64M in Q2 2015.
  • 153 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2016.

Based on Mariner Investment Group's 13F filing for Q1 2016, filed 3 May 2016.